{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052052","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.772413+00:00","generated_at":"2026-06-03T00:24:05.389139+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ultragenyx Q1 2024 revenue $109M (+8% YoY); net loss $171M; reaffirms guidance; pipeline advances","bullets":["Q1 total revenue $109M (+8% YoY); Crysvita $83M (+9%), Dojolvi $16M (+14%).","Net loss $171M ($2.03 per share) vs $164M ($2.33) in Q1 2023; operating expenses $274M.","Reaffirmed 2024 guidance: total revenue $500-530M, Crysvita $375-400M, Dojolvi $75-80M, cash use <$400M.","Positive interim Phase 1/2 GTX-102 data for Angelman syndrome; OI Phase 3 enrollment complete; DTX401 data expected Q2 2024.","Cash and equivalents $569M as of March 31, 2024; net cash used in operations $191M in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052052","json":"https://secwatch.observer/filing/0000950170-24-052052.json","markdown":"https://secwatch.observer/filing/0000950170-24-052052.md","text":"https://secwatch.observer/filing/0000950170-24-052052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024052052/0000950170-24-052052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024052052/rare-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:24:05.389139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8144b35b73b2f2b5bf916c67c3494a15855e531f","claim":"Ultragenyx Pharmaceutical Inc. reported quarter ended March 31, 2024 results: revenue $109 million, net income net loss of $171 million, or $2.03 per share basic and diluted, EPS $2.03 per share basic and diluted. Guidance reaffirmed.","evidence_excerpt":"Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024052052/0000950170-24-052052-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$109 million"},{"label":"Net income","value":"net loss of $171 million, or $2.03 per share basic and diluted"},{"label":"EPS","value":"$2.03 per share basic and diluted"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}